Candorium Free Members
Join Candorium to access the full article and more
Free Member Benefits:
✔
Comment & Reply✔
Newsletter Access✔
Follow Authors✔
Share via SMS Go Back
GSK to buy Affinivax for $3.3 billion to expand vaccine business
By Shubhangi Mathur - May 31, 2022, 04:52 PM ET
Last Updated - Feb 29, 2024, 09:07 AM EST
British pharmaceutical giant GSK plc (NYSE: GSK) on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion
• The company will pay $2.1 billion upfront to Affinivax and up to $1.2 billion in potential development milestones
British pharmaceutical giant GSK plc (NYSE: GSK) on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion.
Sponsored
According to the deal, GSK will pay $2.1 billion upfront to Affinivax and up to $1.2 billion in potential development milestones.
“The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area,” said Dr Hal Barron, Chief Scientific Officer and President R&D.
In an attempt to expand into vaccine business, GSK, which itself is one of the world's major vaccine makers, has invested in the US company.
This is GSK’s second major investment in two months, as the British company bought Sierra Oncology in April for $1.9 billion.
GSK has been under pressure to boost its pharmaceutical business ahead of its separation in July for its consumer business.
Picture Credits: Reuters
ALSO READ:
Sponsored
Read More from Public Health
Read More from Health
Popular News
Latest News
